Healthcare / Drug Manufacturers - Specialty & GenericBSE
$2375.70
-20.65 (-0.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-80.8M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.0B
P/E
38.7x
↑EV/EBITDA
15.4x
↑ROE
11.7%
↑Gross Margin
26.6%
↓Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+32.2%
FCF CAGR
—
FCF margin
6.6%
FCF / Net income
1.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.33B · net income $326.2M · FCF $416.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.33B | $6.33B | $4.52B | $3.47B | $2.74B |
| Net Income | $326.2M | $326.2M | $197.4M | $156.2M | $108.1M |
| EBITDA | $945.4M | $945.4M | $549.1M | $377.7M | $278.8M |
| EPS | — | — | 41.79 | 33.32 | 22.93 |
| Gross Margin | 26.6% | 26.6% | 23.5% | 21.1% | 20.7% |
| Operating Margin | 13.6% | 13.6% | 11.0% | 9.9% | 9.1% |
| Net Margin | 5.2% | 5.2% | 4.4% | 4.5% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.80 | 0.80 | 1.19 | 0.87 | 0.90 |
| Current Ratio | 1.68 | 1.68 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $416.6M | $416.6M | $-351.7M | $-80.8M | $-239.0M |
| Returns | |||||
| ROE | 11.7% | 11.7% | 14.0% | 12.9% | 11.2% |
| Valuation | |||||
| P/E | 38.72 | 38.72 | 16.90 | 23.99 | 38.03 |
| EV/EBITDA | 15.41 | 15.41 | 9.13 | 12.71 | 17.74 |
| P/B | 4.66 | 4.66 | 2.36 | 3.09 | 4.26 |
| Growth & Yield | |||||
| Revenue Growth | 40.2% | 40.2% | 30.3% | 26.3% | — |
| EPS Growth | — | — | 25.4% | 45.3% | — |
| Dividend Yield | 0.0% | 0.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+221.6%
Start / end P/E
n/dx → n/dx
EPS bridge
41.79 → n/d
Residual
+221.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.